Journal of Clinical Oncology (JCO) Podcast cover art

All Episodes

Journal of Clinical Oncology (JCO) Podcast — 465 episodes

#
Title
1

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC

2

JCO Article Insights: Duvelisib in Patients with Relapsed or Refractory PTCL

3

Effectiveness of a Virtual Tobacco Treatment for Cancer Patients

4

Phase 2 Study of Multi-Cancer Detection from Breath Samples

5

JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma

6

JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma

7

JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS

8

JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC

9

JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC

10

Adjuvant Durvalumab and the Future of Early-Stage NSCLC

11

JCO Article Insights: LEAP-010 Study in Recurrent/Metastatic Head and Neck Cancer

12

Infections in Two Diet Strategies in HSCT and Leukemia Patients

13

JCO Article Insights: ctDNA in DLBCL - Ready for Prime Time?

14

The CISTO Study: Radical Cystectomy or Bladder-Sparing Therapy for Recurrent NMIBC

15

JCO Article Insights: Atezolizumab, Bevacizumab, and Non-Platinum Chemotherapy for PROC

16

JCO Article Insights: Ribociclib Plus Letrozole in Recurrent LGSOC: GOG 3026

17

NCI Working Group on Biochemically Recurrent Prostate Cancer

18

Association Between EOL SACT and Healthcare Utilization

19

Milan Consensus Endpoints for Bladder Preservation in MIBC

20

JCO at 2025 ASH: Pirtobrutinib in Untreated CLL

21

JCO at ASH 2025: A New Validated Staging System for AL Amyloidosis: AL-ISS

22

JCO Article Insights: Simultaneous Durvalumab and CRT in Unresectable Stage III NSCLC

23

Health Outcomes in Older Childhood Cancer Survivors

24

Long-Term Remission After Cilta-cel in Patients With RRMM

25

JCO Article Insights: Xevinapant Plus Chemoradiotherapy in Unresected LA SCCHN

26

Income Among Adolescents and Young Adults Surviving Cancer

27

JCO Article Insights: Phase I DLL3/CD3 T-Cell Engager in DLL3-Positive SCLC or NECs

28

TTFields in Locally Advanced Pancreatic Adenocarcinoma

29

JCO at WCLC: Multinational Pivotal Study of Sunvozertinib in Exon20ins NSCLC

30

Racial and Ethnic Disparities Among Medicare Beneficiaries

31

JCO Article Insights: Lymph Node Dissection for Lung Cancer

32

JCO Article Insights: IMS-IMWG Consensus on High-Risk Multiple Myeloma

33

JCO Article Insights: Pooled Taletrectinib Efficacy and Safety

34

JCO at ASCO Annual Meeting: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC

35

JCO at ASCO Annual Meeting: Use of Low-Value Cancer Treatments in Medicare

36

JCO at ASCO Annual Meeting: Avelumab Plus Cetuximab vs. Avelumab in Advanced cSCC

37

JCO at ASCO Annual Meeting: TTFields in Locally Advanced Pancreatic Adenocarcinoma

38

JCO at ASCO Annual Meeting: Lenvatinib Plus Pembrolizumab and Chemotherapy in Gastric Cancer

39

JCO Article Insights: Double Hit Myeloma Correlates With Adverse Patient Outcome

40

Pembrolizumab and Bevacizumab for Melanoma Brain Metastases

41

JCO Article Insights: ESPAC4 Long-Term Follow-Up in Pancreatic Cancer

42

Longitudinal Results from the Nationwide Just ASK Initiative to Promote Routine Smoking Assessment

43

JCO Article Insights: Smoking Assessment

44

Botensilimab Plus Balstilimab in Advanced Sarcomas

45

JCO Article Insights: Long-Term Outcome of Neoadjuvant Chemotherapy for Rectal Cancer

46

High Omega-3, Low Omega-6 Diet with Fish Oil and Prostate Cancer

47

JCO Article Insights: TROPION-Lung01 Dato-DXd in NSCLC

48

Air Pollution and Breast Cancer Incidence

49

JCO Article Insights: Adoption of Capivasertib in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer – Efficacy, Toxicity and Treatment Sequencing

50

Overcoming Barriers to Make Patient-Partnered Research a Reality

51

JCO Article Insights: Nivolumab + Relatlimab v Nivolumab + Ipilimumab in Melanoma

52

Quality of Treatment Selection

53

JCO Article Insights: HLA-Mismatched Unrelated Donor HCT With PTCy

54

Adjuvant Pembrolizumab for High-Risk, dMMR Endometrial Cancer

55

Combining Response and Toxicity Data to Implement Project Optimus

56

CBT-I for Cancer-Related Cognitive Impairment

57

JCO Article Insights: Assisted Reproduction in Breast Cancer Patients

58

Multi-Cancer Early Detection Testing for High-Risk Patients

59

JCO Article Insights: Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade

60

Functional Disability Among US Cancer Survivors

61

CAR T-Cell Therapy for Richter's Transformation

62

EAZ171: Predictors of TIPN in Black Women with Breast Cancer

63

JCO Article Insights: Final Analysis of the Ro-CHOP Trial

64

Methylphenidate for Fatigue in Advanced Cancer

65

Introducing JCO Oncology Advances with Dr. Jonathan Friedberg and Dr. Pamela Kunz

66

JCO Article Insights: Atezolizumab Plus Bevacizumab, Chemotherapy in EGFR, ALK NSCLC

67

Commonly Held Beliefs About Cancer Survivorship

68

JCO Article Insights: Long Term Follow Up of the RESORT (E4402) and LYSA Study

69

Pembrolizumab in Patients With Advanced Cancers With HTMB

70

JCO Article Insights: Axillary Soft Tissue Involvement and Breast Cancer Prognosis

71

Omission of Radiotherapy after Breast-Conserving Surgery

72

Costs of Cancer Prevention in CDH1 Variant Carriers

73

JCO Article Insights: Low and Moderate Grade Adverse Events and the Patient Experience in Clinical Trials

74

Debunking Sex and Disentangling Gender From Oncology

75

Germline EGFR Mutations and Familial Lung Cancer

76

JCO Article Insights: DYPD-Guided Dose Individualization and Survival Outcomes

77

Negative Impact of Prior Authorization on Patients with Cancer

78

Role of Molecular Classification in Predicting Response to Radiation in Early Endometrial Cancer

79

JCO Article Insights: Impact of Physical Activity on Mortality and of BMI on Treatment-Related Adverse Events

80

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

81

JCO Article Insights: Safety and efficacy of a Novel ADC Targeting TROP-2 in Metastatic Non-Small Cell Lung Cancer (NSCLC)

82

Economic Evaluation of a Non-Medical Financial Assistance Program on Missed Treatment Appointments Among Adults With Cancer

83

Disparities in End-of-Life Cancer Care

84

Advance Care Planning in Adolescents and Young Adults with Cancer

85

JCO Article Insights: Improving Lung Cancer Screening Using Blood-Based Biomarkers

86

Impact of Smoking Cessation on Mortality From Kidney Cancer

87

HER3-DXd in EGFR-Mutated NSCLC: HERTHENA-Lung01

88

JCO Article Insights: Introducing The Childhood Cancer Data Initiative

89

Impact of Heatwaves on the Care of Patients With Cancer

90

JCO Article Insights: Immunotherapy in People Living with HIV and Cancer

91

Racial/Ethnic Differences Discovered in Multigene Germline Testing of Early-Onset Colorectal Cancer

92

JCO Article Insights: Two New Prediction Models for Risk of Venous Thromboembolism in Cancer Patients

93

Olanzapine for Chemotherapy-Related Anorexia

94

PROSPECT Trial (Alliance N1048): PROs During and After Treatment for Locally Advanced Rectal Cancer

95

JCO Article Insights: Smoking Cessation for Patients with Cancer

96

JCO Article Insights: Use of Independently-Assessed vs Investigator-Assessed DFS in the APACT Trial

97

Peritumoral Anesthetic Infiltration Impacts Survival in Early Breast Cancer

98

Intensive Caring: Reminding Patients They Matter

99

Barriers to Clinical Trial Participation for Transgender People

100

JCO Article Insights: Trial Update on Development of Children After Maternal Cancer During Pregnancy

101

Cancer Screening During the 2nd Year of the COVID-19 Pandemic

102

Sequencing Matters – Combination Dabrafenib/Trametinib Versus Nivolumab/Ipilimumab for Advanced BRAF-Mutant Melanoma: The DREAMseq Trial

103

JCO Article Insights: Phase III POSEIDON Clinical Trial Results

104

One-Stop-Shop Comprehensive Cancer Screening Center Focused on Asymptomatic Screening

105

Improving Transparency in Phase 1 Clinical Trials

106

JCO Article Insights: Elderly Patients Receiving Chemotherapy for Early-Stage Breast Cancer

107

Ensuring Employment After Cancer Diagnosis

108

Intersectional Maxims for a New Era in Modern Medicine

109

Does Medicare Advantage Lead to a Disadvantage for Patients Who Need Surgery for Cancer?

110

Lack of Gender Equity in Oncology Clinical Trial Advisory Board Membership

111

Universal Germline Genetic Testing in GI Malignancies

112

Light From Darkness - Navigating Postmortem Tissue Donation

113

Physical Activity Improves Survival in Colorectal Cancer

114

Food Insecurity Interventions for Cancer Survivors With Dr. Francesca Gany and Dr. Theresa Hastert

115

How to Confront Climate Change: A Framework for Change in the Operating Room and Hospital as a Whole. A Conversation with Dr. Anaeze Offodile and Dr. Elizabeth Yates

116

JCO After Hours: A Discussion With Veena Shankaran and Scott Ramsey

117

JCO After Hours: A Discussion With Virginia Sun

118

JCO After Hours: A Discussion With Antonio Di Meglio

119

JCO After Hours: A Discussion With Abby Rosenberg and Reshma Jagsi

120

JCO After Hours: A Discussion With Michael Gnant and Kathy Miller

121

JCO After Hours: A Discussion With Kirsten Beyer and Jennifer Griggs

122

Is Dose-Adjusted EPOCH-R the Optimal Treatment for Children with Primary Mediastinal B-Cell Lymphoma?

123

Steroid Dose and Taxanes

124

Commentary on GROINSS VII

125

Harnessing the Power of Registries to Understand the Impact of Treatment for Hodgkin Lymphoma on Fertility

126

Subspecialty Palliative Care Involvement May Lessen the Need for High-Intensity End-of-Life Care for Adolescents and Young Adults With Cancer

127

Can the Incorporation of Minimal Residual Disease Detection Enhance Post-CAR T Outcomes in Patients With Large B-Cell Lymphoma?

128

Moving Forward With Venetoclax-Based Combinations in Younger Adults With Acute Myeloid Leukemia

129

A Deep Dive Into HLA Typing For Unrelated Donor Hematopoietic Cell Transplantation

130

PENELOPE-B: Exploration of CDK4/6 Inhibition in the Adjuvant Setting

131

ctDNA in DLBCL: A Blueprint for Better Clinical Trials?

132

How Can We Expand Eligibility Criteria for Diffuse Large B-Cell Lymphoma Clinical Trials to Serve More Patients?

133

The Pathologist, the Surgeon, and the Rare Phyllodes Tumor

134

Cancer Surgery in COVID-19-Free Facilities

135

Finding a Needle in a Haystack of Mutations: Using Whole Genome Sequencing to Identify Patients with Low-Risk Myeloma

136

Advancing Knowledge on the Use of Dexrazoxane in Children With Acute Myeloid Leukemia and Other Childhood Cancers

137

Better Diet – Fewer Side Effects?

138

Genetic Testing in Breast Cancer Patients: Striking the Balance Between Over Versus Undertesting

139

High Reward, High Toxicity: Combination Pembrolizumab and Lenvatinib in Advanced Endometrial Cancer

140

Optimizing Treatment Strategies for Germline BRCA/PALB2 Mutant Pancreatic Adenocarcinoma

141

Immune Checkpoint Inhibitor Use in Patients With Inflammatory Bowel Disease: A Closer Look

142

The High Prevalence of Exercise Intolerance in Adult Survivors of Childhood Cancer Is Predictive of All-Cause Mortality

143

Leptomeningeal Disease in EGFR-Mutated Lung Cancer: Can We Finally Define a Standard Treatment?

144

Advancing Treatment Options for Mismatch Repair-Deficient Metastatic Colorectal Cancers

145

Keeping Mycosis Fungoides in Check: A Study of Pembrolizumab for Relapsed/Refractory MF and Sezary Syndrome

146

What's in a Name? An Introductory Guide

147

Resuming Life After Cancer Therapy: Treatment-Free Survival

148

Intratumoral Immune Infiltration in Follicular Lymphoma: Novel Insights into Early Relapse and Survival

149

MYC Rearrangements in Diffuse Large B-Cell Lymphoma: Impact and Implications for Diagnostic Testing

150

Centralization of High-Risk Surgery: Real Benefits for Patients From Health Systems

151

Microsatellite Instability as a Prognostic Marker for Resectable Gastric Cancer and a Potential Biomarker for Perioperative Chemotherapy Benefit

152

Radiotherapy Dose Reduction Is Possible With Induction Chemotherapy for Pediatric Nasopharynx Cancer

153

Fine Tuning Therapy for Intermediate-Risk Neuroblastoma Using Clinical Response and Tumor Biology

154

Déjà Vu or Predicted: The Failure of Dose Adjusted EPOCH-R to Improve Outcomes in Diffuse Aggressive Lymphomas

155

Tackling Stage III EGFR Mutation-Positive Lung Cancer: Do We Really Know How?

156

The Need for Continued Vigilance in Patients with Diffuse Large B-Cell Lymphoma

157

A Second Chance at Checkpoint Inhibition After Initial Immune-Mediated Diarrhea and Colitis

158

Anticipating the Future of Hodgkin Lymphoma

159

An Advance for the Treatment of Osteosarcoma

160

The Heartbreak of Cancer Treatment: The Latest in Late Cardiac Toxicity

161

Programmed Cell Death-1 Pathway Inhibitors Enter Center Stage as First-Line Treatment of Advanced Merkel Cell Carcinoma

162

Potential for Parenthood After Childhood Cancer: Perceptions and Reality

163

How Should We Interpret Indeterminate Pulmonary Nodules at Diagnosis in Children With Rhabdomyosarcoma?

164

The End of ENDoxifen Metabolite and CYP2D6 Testing in Tamoxifen-Treated Women?

165

Less is More: Precision Surveillance Imaging for Wilms Tumor

166

How Low Can You Go? Impact of Baseline Corticosteroid Use on Immunotherapy Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer

167

Expanding Treatment Options for Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer

168

The Addition of Another Camptothecin Fails to Improve Outcomes in Patients With Intermediate-Risk Rhabdomyosarcoma

169

The Addition of IKZF1 Deletion in Risk Stratification for Children with Newly Diagnosed B-Acute Lymphoblastic Leukemia Leads to Improved Survival: Results of the Malaysia-Singapore ALL 2010 Study

170

Psychosocial Outcomes Following Contralateral Prophylactic Mastectomy: Insights and Opportunities

171

Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms

172

Don't Treat Me Like a Child: The Intensification of Conventional Chemotherapy in Adults With Acute Lymphoblastic Leukemia

173

Multiple Myeloma Joins the Car T Race

174

Cardiotoxicity After Breast Cancer Radiotherapy: Which Part of the Heart Matters Most?

175

Should Prophylactic Cranial Irradiation Be Used in Patients with Stage III Non-Small Cell Lung Cancer?

176

The Medical Marijuana Conundrum: When Public Interest Outpaces Medical Knowledge

177

Racial Disparities in Medical Financial Hardship Among Cancer Survivors

178

Late Infectious Death: Asplenic Adult Survivors of Child Cancer

179

Extending the Reach of Targeted Therapy for Hormone Receptor-Positive Advanced Breast Cancer

180

An International Phase II Trial of Single-Agent Nivolumab for Hodgkin Lymphoma Relapsed or Refractory After Autologous Stem Cell Transplant

181

Exploring a New Delivery Model for Germline Genetic Testing for Patients With Ovarian Cancer

182

Is Earlier Treatment Better For Patients? The Case of Docetaxel in Metastatic Castration-Sensitive Prostate Cancer

183

The Decision to Image Breast Cancer Patients with Local-Regional Recurrence

184

The Importance of Reading Clinical Trial Protocols Simultaneously With Published Studies

185

Understanding the 'Value-Added' by Specialized Pediatric Palliative Care Teams in the Care of Children With Cancer at the End of Life

186

Survival Following Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Early-Stage Hepatocellular Carcinoma

187

The True Costs of the 21-Gene Assay in a Cohort of 1,000 Patients

188

Persistent Use of Opioids After Cancer Surgery

189

Discussion on the Cost–Effectiveness Analysis of the CALGB/Alliance Trial and the Use of Zoledronic Acid Generic in Women With Metastatic Breast Cancer

190

Can We Simplify the Treatment of Myelofibrosis?

191

Lessons to be Learned about the Significance of Educational Level in Adults with Acute Myeloid Leukemia

192

More Often but Not Early: Hospice Use Among Older Adults With AML

193

T-cell Therapy for Viral Infections after Stem Cell Transplant

194

Shared Risk Factors in Cancer and Cardiovascular Disease: Can We Make a Difference?

195

Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?

196

Considerations in Predicting Neuropsychological Outcomes in Children Treated for ALL

197

Low-Income Subsidy and Financial Barrier to Access Costly Oral Chemotherapy Drugs for Myeloma Patients Enrolled in Medicare Part D

198

Beyond the Beam: Thinking about Subsequent Malignancy Risk Outside of the Radiation Paradigm,"

199

Discussion of the SWORD-Study and Fear of Cancer Recurrence Intervention Research Randomized Controlled Trial

200

Optimizing Up-Front Therapy for Double-Hit Lymphoma

201

Chronic Conditions in Cancer Survivors

202

Do Treatment Summary Survivorship Plans Make Any Difference?

203

The Impact of Cigarette Smoking on Survival in Patients with Pancreatic Cancer

204

Better Patient-Reported Outcomes After Autologous Breast Reconstruction Compared to Implant-Based Reconstruction Study

205

Drugs Don't Work in Patients Who Don't Take Them

206

Pembrolizumab is Safe and Active in Platinum- and Cetuximab-Refractory Head and Neck Squamous Cell Carcinoma

207

Long-Term Follow-up of AF-001JP: A Phase I/II Study of Alectinib in ALK-Positive NSCLC

208

Late Relapse in Hodgkin Lymphoma Persisting Even at 20 Years: Implications for Therapeutic Intensity and Disease Biology

209

Intensification of Consolidation Therapy for Acute Myeloid Leukemia by the Addition of Clofarabine to Cytarabine Improves Relapse-Free Survival

210

Characterizing the Patterns of Clonal Evolution in Ibrutinib-Treated CLL: A Roadmap for Continued Progress

211

Prevalence of Germline Mutations in Individuals With Colorectal Cancer as Determined Using a Multi-Gene Panel Test

212

Financial Barriers to Cancer Care for Patients Obtaining Insurance on the Federal Exchange

213

Mindfulness-Based Interventions in Oncology: Not for Everyone?

214

The Impact of Oral Targeted Therapies on the Cost of Care for Patients With Chronic Lymphocytic Leukemia

215

Watching Nivolumab's Balancing Act: How Immune Activation May Affect Both Safety and Efficacy in Patients With Advanced Melanoma

216

Getting to the Heart of the Matter: Biomarkers for the Assessment of Trastuzumab-Induced Cardiac Dysfunction

217

Listen to Your Patients

218

Impact of Organizational Characteristics and Process of Care on Hospital Mortality and Resource Use in Cancer Patients Admitted to Intensive Care Units

219

Health-Related Quality of Life: Increasingly Important in the Era of Effective, Modern Myeloma Therapy

220

Chemotherapy Induced Peripheral Neuropathy: A Novel Method of Exploration

221

Changes in the Epidemiology of AIDS-Related Kaposi's Sarcoma and Lymphomas: How This Informs the Clinician

222

Implicit Racial Bias Affects Key Aspects of Physician Communication

223

Nivolumab Monotherapy is Safe and Active in Hematologic Malignancies

224

Minimizing Frailty in Cancer Survivors: A Meaningful Goal for All Ages

225

1q Gain, a Prognostic Biomarker in Nephroblastoma, and What's Next?

226

Therapy Impacts Long-Term Survival for Patients in Germany With Heritable Retinoblastoma

227

Dexamethasone and High-Dose Methotrexate in High-Risk B Cell Acute Lymphoblastic Leukemia—Where Should We Go From Here?

228

Unraveling the Significance of Mismatch Repair Deficiency in Women With Endometrioid-type Endometrial Adenocarcinoma

229

Nodal Status After Neoadjuvant Chemotherapy Determines Prognosis in Localized Gastric Cancer

230

Restrictions on Nutrition, Social Contacts, and Pets Are Not Effective Anti-Infective Measures in Children With Acute Myeloid Leukemia

231

Current Status of Supplemental Screening in Dense Breasts

232

Selective Internal Radiation Therapy for Liver-Dominant Metastatic Colorectal Cancer: Time to Put the Brakes On?

233

Prognostication Based on Site of Metastatic Disease in Castration Refractory Prostate Cancer: Implications for Patient Care and Clinical Trial Design

234

IgM-Related AL Amyloidosis: A Rare Form of a Rare Disease

235

Quality of Life: A Critical Consideration in Women Diagnosed with Ductal Carcinoma in Situ

236

Very Late Outcomes of Wilms Tumor Survivors: British Childhood Cancer Study

237

Web-Based Technology Can Improve Patient Understanding and Preparedness to Discuss Cancer Clinical Trials: One Step Towards a Goal of Increased Enrollment

238

How Should We Manage the Financial Toxicity of Cancer Treatment?

239

Prognostication in Mantle Cell Lymphoma

240

Sunbelt Melanoma Trial: A Seminal Adjuvant Interferon Trial with Long Term Results

241

Hepatocellular Carcinoma in Children and Adolescents: Time for a Strategy and a Trial

242

Clinical Drug Development for Non-Muscle-Invasive Bladder Cancer…Definitions Matter

243

Race for the Cure: How differences in Race and Ethnicity Impact the Diagnosis and Survival of T-Cell Lymphoma

244

Epidural Spinal Cord Compression: The Importance of Multi-disciplinary Treatment Planning

245

Hard to RECIST: Updating and Simplifying Primary Tumor Response Guidelines for the Revised International Neuroblastoma Response Criteria (INRC)

246

Expanding Immunotheapy Benefit in Metastatic RCC

247

A New Oncogene Target in Lung Cancer: Exon 14 Alterations in the MET Gene

248

The Evolution of the Polycythemia Vera Symptom Burden: Implications for a Changing Treatment Paradigm

249

The Emerging Role of Gallium-68 Somatostatin-Receptor PET Imaging in Neuroendocrine Tumors

250

Dexrazoxane for childhood cancer patients – ready for prime time?

251

Uterine lavage: a new approach to gynecologic cancer detection?

252

Hormonal Therapy is Out for Meningiomas: Time to Change Tactics?

253

Defining the Optimal Interval for Colonoscopic Screening in Individuals with a Family History of Colorectal Cancer

254

Using the CLIC Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome to Guide Treatment And Clinical Research

255

Geographic Access as a Barrier to Adjuvant Chemotherapy for Patients with Stage III Colon Cancer

256

Host Factors and Lynch Syndrome Patients: Weighing Role of Obesity and Aspirin and Risk of Colorectal Cancer

257

To Stop or Not to Stop: That is the Question

258

Breast Cancer and Weight Loss: Where Do We Go from Here?

259

The Promise and the Pitfalls of Population-Wide Screening of BRCA1 and BRCA2

260

Intraperitoneal Therapy for Ovarian Cancer: No More Excuses

261

Balancing Safety and Efficacy in the Treatment Hodgkin Lymphoma: Early Discontinuation of Certain Drugs Can and Should Be Done

262

When Toxicity and Efficacy Collide

263

First Results of Euramos I and Logistics of International Collaboration for Clinical Trials of Rare Diseases

264

Treatment Advances in Local-Regionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree that More Isn't Always Better?

265

Androgen Deprivation Therapy for Prostate Cancer - Friend or Foe to the Psyche?

266

Building Blocks in the Case for Adjuvant Therapy in Biliary Tract Cancers

267

Aromatase Inhibitor Arthralgias: Identification, Treatment Options and Research Perspectives

268

Deciphering the Heterogeneity Within EGFR-mutant Lung Cancer

269

Precision Immunology: The Promise of Tumor Immunotherapy for the Treatment of Cancer

270

The Importance of Discussing Genetics with Every Breast Cancer Patient

271

Hematopoietic Stem Cell Transplant for Children With Acute Lymphoblastic Leukemia at BFM Centers: Comparable Results With Matched Sibling Donors and Matched Unrelated Donors

272

Is It Biology or Brawn in Ovarian Cancer Surgery?

273

Mirror Views: Reflections of Complementary Perspectives in Patient and Clinician Toxicity Reporting

274

Dynamic Evolution of ALK Positive Non-Small Cell Lung Cancers and Management of Associated Brain Metastases

275

Prediction of Breast Cancer Risk After a Benign Breast Biopsy: A Practical Model?

276

Prophylactic Anticoagulation in High-Risk Metastatic Germ Cell Tumor Patients: Who Should We Treat?

277

The Risk of Second Cancers for Patients with Endometrial and Rectal Cancer Receiving Radiation Therapy

278

Better Outcome of Chemo-Irradiation of Head and Neck Cancer in High-Patient-Volume Institutions

279

Is There a Future for Cyclooxygenase-2 Inhibition in Non-Small Cell Lung Cancer?

280

The Treatment of Insomnia in Cancer Patients

281

The Biopsy Study: How the Use of Multiple Colposcopic-Directed Biopsies Improves Detection of Cervical Precancers

282

Intensified Frontline Chemoimmunotherapy with R-ACVBP May Improve Outcomes for Younger Patients with Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

283

A Positive Study of DTC-Guided Secondary Adjuvant Treatment in Early Breast Cancer: Ready for Prime Time?

284

A Second Course of Radiation Therapy for Painful Osseous Metastases Improves Patient Function and Quality of Life

285

Adjuvant Trastuzumab Passes the Test of Time

286

Prognostic Value of BRAF V600 E Mutation in Papillary Thyroid Cancer

287

Biochemotherapy: As Time Goes By?

288

The First Prospective Trial of Proton Therapy for Children With Rhabdomyosarcoma: What We Learn From Preliminary Results

289

Intermediate Risk Pediatric Hodgkin Lymphoma: Early Response-Adapted Treatment Is Key

290

Keeping Older Cancer Patients out of the Hospital: A Community Affair

291

Optimal Duration of MRD Monitoring During Therapy for Childhood ALL

292

Hepatitis B Reactivation in Patients Receiving Rituximab Can Be Detected Early and Managed with Antivirals

293

CT or No CT: An Important Question in Diffuse Large B-Cell Lymphoma

294

Glembatumumab Vedotin (CDX-011, CR011-vcMMAE): On The Brink Of Targeted Therapy For Triple-Negative Breast Cancer?

295

Post-Transplant Cyclophosphamide for GVHD Prophylaxis: Back to the Future

296

The Price Of A Drug is Not the Whole Cost

297

Cabozantinib in Advanced Prostate Cancer: Is the Therapeutic Window Too Narrow?

298

Fracture Risk after Cystectomy: Don't Ignore It

299

Is Hematopoietic Stem Cell Transplantation of Value in Treating Systemic Mastocytosis?

300

Significant Dose Effect of Radiotherapy to the Pancreas and Risk of Diabetes Mellitus in Long-Term Hodgkin Lymphoma Survivors

301

The End of Rituximab Maintenance for Low Tumor Burden Follicular Lymphoma

302

Use of Mutational Analysis to Help Decide Whether Patients with Myelodsysplastic Syndromes Should Receive Allogeneic Hematopoietic Cell Transplant

303

Why are Fellows' Burnout Rates as High as Those of Practicing Oncologists?

304

Surprisingly Good Results in BCR-ABL1-like Pediatric Acute Lymphoblastic Leukemia: What Do They Mean?

305

Should Corticosteroids Be Used for the Treatment of Pain, Fatigue and Loss of Appetite in Cancer Patients Receiving Opioids?

306

Breast Reconstructions: Inequities in Access Affecting Choice and Quality

307

Recurrent/Metastatic Human Papillomavirus-Associated Oropharynx Cancer: What Happens When This Good Prognostic Cancer Misbehaves?

308

Long Term Cardiac Safety Data from the HERA Adjuvant Trastuzumab Trial

309

Breast Needle Core Biopsy: The Impact Surgeons and Geography Have on Utilization and the Impact on Patient Care

310

Identifying High-Risk Myeloma

311

Attempting to Avoid Chemotherapy in CLL with Lenalidomide and Rituximab

312

Breast Cancer Chemotherapy Effects on Brain Activation During Multitasking and Relation to Cognitive Complaints

313

Delayed Diagnostic Lumbar Puncture to Optimize Central-Nervous-System-Directed Therapy in Childhood Acute Lymphoblastic Leukemia

314

Capecitabine Versus Continuous Infusion 5-FU for Rectal Cancer Neoadjuvant Chemoradiation: Equivalent Effectiveness Raises Real-World Questions About Efficacy, Adherence and Economic Implications

315

Evolving Treatment Paradigms for Primary Mediastinal Diffuse Large B-Cell Lymphoma

316

Response Assessment in Hodgkin Lymphoma: Size Matters!

317

Second Tumors in PTEN Mutation-Positive Patients: Are They Recurrences or New Primaries?

318

Are Partners of Patients HPV-Positive Oropharyngeal Cancer at Increased Risk of Infection and Cancer?

319

Planning to Survive: The Role of Physicians

320

Minimal Residual Disease (MRD) Study to Optimize Definition and Therapy of High-Risk Acute Lymphoblastic Leukemia

321

Risk-Reducing Oophorectomy in Women with BRCA1 and BRCA2 Mutations: An Opportunity to Personalize Recommendations for Cancer Prevention

322

Anti-EGFR Monoclonal Antibodies in the First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The PEAK Experience

323

Accuracy of BRCAPRO in Women with Ovarian Cancer

324

Serious Bevacizumab-Associated Gastrointestinal Toxicity

325

The Efficacy of Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer Patients and Its Effects On Patient-Reported Outcomes

326

Nivolumab: Promising Survival Signal Coupled with Limited Toxicity Raises Expectations

327

Decision Shared or Otherwise-: The Ongoing Evolution of Local Therapy for Breast Cancer

328

Is Early Initiation of Adjuvant Chemotherapy for Breast Cancer Better?

329

Single Agent Rituximab Active in Nodular Lymphocyte Predominant Hodgkin Lymphoma

330

Adjuvant Treatment for Gastric Cancer: The Story Continues to Evolve

331

Benefits of Modified Craniospinal Radiation Therapy for Children Treated for Medulloblastoma: Preserving Long-Term Neurocognitive Function

332

Breast MRI As It Is, In Contrast To How We Wish It To Be

333

New Adoptive T Cell Therapy Has EBV-Positive Lymphomas on the Run

334

Adjuvant High-Dose Interferon: New Evidence Regarding Treatment Duration and Survival Impact in Melanoma

335

Some like It Even Hotter: Escalating Radioimmunotherapy in Follicular Lymphoma?

336

Increasing Cytarabine Dose in AML Induction Improves Outcomes in Younger Patients

337

The Value of Preoperative MRI in Predicting Outcome in Patients with Rectal Cancer

338

Refining Stringency of Response in Myeloma

339

When Hodgkin Lymphoma Relapses in The Older Patients

340

How Do We Decide Who Should Be Offered a Sentinel Node Biopsy When Their Melanoma Is Less than 1mm in Thickness?

341

FISH for Smoldering Multiple Myeloma

342

External Beam Accelerated Partial Breast Irradiation: Exploring the Limits of Tolerability

343

Minimal Residual Disease (MRD) in Acute Myeloid Leukemia- Are we Ready for Individualized Risk Assessment Based on MRD?

344

Functional Imaging as a Biomarker for Survival in Locoregionally Advanced Non-Small Cell Lung Cancer Patients

345

EORTC 18961 GMK Vaccine Adjuvant Trial: Unfulfilled Promise for Another Vaccine Trial

346

Lenalidomide Monotherapy for Relapsed Mantle Cell Lymphoma

347

Flying Solo: Chemotherapy Without Radiation for Primary Central Nervous System Lymphoma

348

Second Hematopoietic Transplants for Relapsed AML

349

In End-Of-Life Decision-Making, Does DNR Measure Up?

350

A Clear Answer to the Wrong Question

351

Bisphosphonate-Related Osteonecrosis of Jaw (BOJN) in the Adjuvant Breast Cancer Setting: Risks and Perspective

352

Should Myeloma Residual Disease Become a Standard Assay for Large Cooperative Groups and Myeloma Referral Centers?

353

The Prognosis of Breast Cancer Diagnosed During Pregnancy

354

The SUCCEED Trial: Maintenance Ridaforolimus for Metastatic Soft- Tissue Sarcomas

355

Who Needs What Therapy? The Elusive Search for Predictive Markers

356

Micro RNAs and Other Molecular Markers in AML Therapeutics

357

Neuroanatomic and Neuropsychological Outcomes in Adults after Treatment for Childhood Acute Lymphoblastic Leukemia

358

HERA Indicates that Adjuvant Trastuzumab Confers Equal Benefit for HER2-Positive Invasive Ductal and Invasive Lobular Breast Cancers

359

New Evidence of the Clinical Significance of Cigarette Smoking by Colon Cancer Patients

360

Radiotherapy for Pediatric Hodgkin Lymphoma: Are We Ready To Say Goodbye?

361

Minimal-Intensity Conditioning: A Decade Later

362

Evolution of Concurrent Chemoradiation Treatment Approaches in Head and Neck Cancer

363

Off-Label Cancer Therapy Use: How Much is Too Much?

364

Caring For Patients With Transformed Follicular Lymphoma

365

Outpatient Therapy for Fever and Neutropenia is Safe But Implementation is the Key

366

Outcomes in Cancer Survivors Who Develop Second Malignant Neoplasms

367

Molecular Profiling of Gastric Cancer: Toward Personalized Cancer Medicine

368

Reflections on "Cancer Survivorship": Evolution, Utility, and Acceptability

369

Estimating the Risk for Contralateral Breast Cancer as a Guide for Surgical Treatment

370

Revisiting Combination TACE-RFA Treatment for HCC

371

Novel Insights From a Phase II MEK Inhibitor Trial in BRAF Mutant Melanoma

372

Successful Non-Intensive Bridging of MDS Patients Towards Allografting

373

Using a Video Decision Support Tool for CPR Decision-Making

374

Radioimmunotherapy for the Initial Treatment of Follicular Lymphoma

375

Management of Metastases to the Brain: A Therapeutic Conundrum

376

Understanding the Role of MET Kinase in Cancer Therapy

377

AIDS Related Lymphomas - More Options and More Questions

378

Long Term Follow-up of NSABP B-31: How Well Can We Predict Cardiac Toxicity with Trastuzumab?

379

More Adjuvant Chemotherapy is Not Always Better

380

Hodgkin Lymphoma: Protecting the Victims of Our Success

381

Beyond the Plasma Cell: Proteasome Inhibition in Acute Myelogenous Leukemia

382

Breast Brachytherapy in the United States: Increasing Use Despite Increased Complication Rates

383

Referral Practices to Palliative Care Among Canadian Oncologists

384

Clinical Utility of Screening Tests in Asymptomatic Long-Term Childhood Cancer Survivors

385

Is Lymphatic Mapping Ready for Clinical Use in the Treatment of Squamous Vulvar Cancer?

386

Rituximab Maintenance Therapy After Autologous Stem Cell Transplantation: Final Analysis of the CORAL Trial

387

Informed Consent for Pediatric Phase I Cancer Trials: An End-of-Life Decision

388

Outcome in Systemic Anaplastic Large Cell Lymphoma: Beyond ALK

389

Should Gemtuzumab Ozogamicin Be Re-added to the Therapeutic Armamentarium for Acute Myeloid Leukemia?

390

Immunohistochemical Double Hit Score in Diffuse Large B-Cell Lymphoma: The Potential to Screen All Tumors for High-Risk Biology

391

In a Sea of Data the Water is Still Murky: Meta-Analysis of Cognition in Breast Cancer

392

KRAS G13D Mutations in Metastatic Colorectal Cancer: Are They Different From Codon 12?

393

Taxane Induced Peripheral Neuropathy: A Continued Challenge but Not a Biomarker of Treatment Efficacy

394

Is This Nomogram Ready To Roll?

395

Adjuvant Chemotherapy in Older Patients with Stage III Colon Cancer

396

The Combination of Bortezomib, Thalidomide, and Dexamethasone in Relapsed Multiple Myeloma

397

Personalized Therapy for Breast Cancer: Is It Really Happening?

398

Routine Second Pathology Review for Node-Negative Breast Cancer: What is Learned and What is the Effect on Patient Care?

399

Pre-Operative Metformin in Early-Stage Breast Cancer

400

Fulvestrant and Anastrozole in Combination: FACT or Fiction?

401

A New Day Dawning for Hodgkin Lymphoma?

402

The German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow Up of 11 Years: Implications of Long Term Follow Up

403

Carboplatin-Gemcitabine-Bevacizumab: Expanding Treatment Options for Recurrent Platinum Sensitive Epithelial Ovarian Cancer

404

The Use of Adjuvant Therapy in Elderly Patients with Resected Non-Small Cell Lung Cancer (NSCLC)

405

Management and Prevention of Pain Related to Treatment or Disease

406

1 + 1 = 3. Combined Use of Anti-HER2 Agents in the Neoadjuvant Setting

407

Management of Low Stage Ovarian Clear Cell Carcinoma

408

Surviving Childhood Cancer: Defining Risk of Poor Cardiac Outcomes in Early and Middle Adulthood

409

No Advantage to Combining Cetuximab with 5FU, Leucovorin, and Oxaliplatin in Metastatic Colorectal Cancer

410

Sorting Through Early Melanomas to Identify Those at Higher Risk for Metastases

411

Sedation for the Management of Refractory Suffering

412

The Role of the Estrogen Receptor (ER) in Selecting Women, Diagnosed with DCIS for Adjuvant Therapy with Tamoxifen

413

How Cooperative Group Trials Impact Breast Cancer Care in United States

414

What's Different Between One Colorectal Cancer and Another? It's All in the Genes

415

Molecular Tumor Analyses Followed by First Line Oral Tyrosine Kinase Inhibitors in Lung Adenocarcinomas with Driver Abnormalities

416

Placing the P Value into Perspective: Does Paclitaxel Add Value to Gemcitabine and Cisplatin in Advanced Urothelial Cancers?

417

Early Stage Hodgkin Lymphoma -- How Much is Enough?

418

The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia

419

Rethinking Our Use of CSFs in the Adjuvant Treatment of Women Who Have Estrogen Receptor Positive Cancers

420

Recurrence and Survival Results of the GOG Lap2 Trial Confirm Safety of the Laparoscopic Approach to Surgical Staging and Treatment for Uterine Cancer

421

"Anything You Can't Do, I Can't Do Either": Transplantation for High Risk AML

422

Safety and Efficacy of Sequential Adjuvant AI Therapy in ER Positive Breast Cancer

423

The Role of Ovarian Suppression for Fertility Preservation in Women Receiving Adjuvant Breast Cancer Chemotherapy

424

Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict Long-Term Outcome for Patients with CML Treated with Imatinib

425

The Importance of Tumor Biopsies for Analysis of Mechanisms of Response and Resistance in Prostate Cancer

426

Targeting the Angiopoietin-Tie2 Axis: A Promising Alternative Antiangiogenic Strategy for Epithelial Ovarian Cancer

427

Interim PET Scans in Diffuse Large B-Cell Lymphoma - More Than Another Biomarker?

428

To Biopsy or Not to Biopsy? That is the Question

429

Disparities in Systemic Therapy for Breast Cancer

430

Adjusting for Treatment Cross-Over to Enable Analysis of Longer Term Outcomes in the MA.17 Trial

431

Obesity and Colorectal Cancer: What's the Big Deal?

432

Combinations or Single Agents, Crossover or No Crossover: Considering Chemotherapy Strategies in the Multi-Chaptered Story of Metastatic Breast Cancer

433

Medical Oncologist Attitudes and Practice in Cancer Pain Management: A National Survey

434

Is a "Wait and See" Nonoperative Approach Justified after Chemoradiation for Rectal Cancer

435

Predictive Testing for BRCA1/2 Mutations: The Value of the "True"Negative

436

Trastuzumab in the Adjuvant Setting - Sequential versus Concurrent: Will We Ever Know the Full Answer?

437

Solving the Mystery of Recurrence in "Surgical Cures" for Early Non-Small Cell Lung Cancer

438

Comorbidity Data in Cooperative Trials: Feasible and Non Ignorable

439

Gender Equity and HPV-Associated Cancers in the United States

440

Biomarker Selection for Maintenance Therapy in Advanced NSCLC

441

Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia

442

R-CHOP Chemotherapy as Upfront Treatment for Advanced Stage Follicular Non-Hodgkin Lymphoma

443

Venlafaxine and Clonidine for Treatment of Hot Flashes in Women with Breast Cancer

444

Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Non-Carriers: A Single Institution Experience

445

Individualizing the Risk of Cardiovascular Mortality Following Androgen Deprivation Therapy for Prostate Cancer

446

High Risk Stage II Colon Cancer: What is the Role of Adjuvant Chemotherapy?

447

Is Genotype Guided Tamoxifen Dosing Ready for Prime Time?

448

Menopausal Hormone Therapy, Mammographic Density and Breast Cancer

449

The Growing Value of Risk Calculators for Men Considering Prostate Cancer Screening

450

Interpretation of the Biomarker Analysis and Final Overall Survival Results from IPASS

451

Curing Leukemia with a Single Drug

452

Vaccination with an Autologous Idiotype Based Vaccine Following a Chemotherapy Induced Remission Holds Promise in the Treatment of Patients with Follicular Lymphoma

453

Pathologic Complete Response and Toxicity Results from the STAR-01 Trial Evaluating the Addition of Oxaliplatin to Neodjuvant Chemoradiation for Locally Advanced Rectal Cancer

454

MEK Inhibitors

455

Angiogenic Therapy in Breast Cancer: Axitinib with Chemotherapy Joins the Crowd

456

Advanced Radiation Therapy Technology Improves Survival in Lung Cancer

457

The Dark Side of del(5q) MDS

458

Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer: Is it Ready for Prime Time?

459

Are Lung Cancers with BRAF Mutations Another Molecularly Defined Subgroup of Patients?

460

Targeting the VEGF Receptor in Colon Cancer: Lessons Learned from Negative Trials

461

The Performance of Breast MRI Screening Among Women with BRCA1/2 Mutations

462

Circulating Tumor Cells in Resectable Colorectal Cancer

463

Results From a Phase I Trial of TG101348, a Selective JAK2 Inhibitor with Significant Activity in Symptomatic Myelofibrosis Patients

464

RIBBON-1 Revisited

465

Noninferiority of Denosumab As Compared With Zolendronic Acid With Respect to the Ability to Delay Skeletal Events in Patients With Solid Tumors and Multiple Myeloma